Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 567
National Institute for Health and Care Excellence (NICE)
Record ID 32018011628
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta567
Year Published:
2019
URL for published report:
https://www.nice.org.uk/guidance/ta567
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Lymphoma, Large B-Cell, Diffuse
- Receptors, Chimeric Antigen
- Antineoplastic Agents, Immunological
- Receptors, Antigen, T-Cell
- Immunotherapy, Adoptive
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.